Toxicidad pulmonar por talidomida

Valero, F. Carrión

doi:10.1016/s0300-2896(02)75272-1

Cited by 27 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A case report described a pattern of right-side heart failure and concomitant dyspnea, with features of interstitial pneumonia on a chest X-ray [7]. On discontinuing the thalidomide, this patient's symptoms improved; however, because no chest CT or bronchoscopic findings were described in this case, it could not be concluded that the pulmonary side effects were definitely caused by thalidomide.…”

Section: Discussionmentioning

confidence: 91%

Thalidomide Induced Nonspecific Interstitial Pneumonia in Patient with Relapsed Multiple Myeloma

Kang

Kim

et al. 2010

Korean J Intern Med

View full text Add to dashboard Cite

A 63-year-old female diagnosed with relapsed multiple myeloma visited our hospital complaining of a persistent cough. Since July 2006, she had been taking 100 mg thalidomide daily and gradually developed shortness of breath and a persistent dry cough. A chest X-ray and computed tomography showed ground glass opacities in both lungs. An open lung biopsy of the right middle lobe under general anesthesia revealed chronic peribronchial inflammation, mild interstitial fibrosis, and intra-alveolar macrophage infiltration, with some hemosiderin features, compatible with non-specific interstitial pneumonia (NSIP). After discontinuing the thalidomide, the patient's symptoms did not deteriorate, although the radiographs did not improve. The patient is alive and well with regular outpatient follow-up without progression of the NSIP.

show abstract

Section: Discussionmentioning

confidence: 91%

Thalidomide Induced Nonspecific Interstitial Pneumonia in Patient with Relapsed Multiple Myeloma

Kang

Kim

et al. 2010

Korean J Intern Med

View full text Add to dashboard Cite

show abstract

“…Patients present with fever and asthma like symptoms which progress to respiratory failure and pulmonary infiltrates (98). There have also been reports of lung toxicity following Thalidomide (99) and Lenalidomide(100) with toxic granulomatous interstitial pulmonary disease which is steroid responsive.…”

Section: Systemic Al Amyloidosismentioning

confidence: 99%

Amyloidosis and the Lungs and Airways

Lachmann

Pinney²

2023

Orphan Lung Diseases

View full text Add to dashboard Cite

show abstract

“…Adverse events (typically constipation, dizziness or malaise) were, however, reported in 74% of patients receiving thalidomide compared with 22% receiving placebo. These findings suggest that thalidomide may be an effective therapy for symptomatic treatment of chronic cough in patients with IPF; however, this was a small single-centre trial and thalidomide has been associated with the development of acute interstitial lung processes [65,66,67,68] and thromboembolic events [69]. Further multi-centre studies are therefore essential to confirm both safety and efficacy of thalidomide in the treatment of chronic cough in IPF.…”

Section: Recent Significant Clinical Trials (2010 Onwards)mentioning

confidence: 99%

Idiopathic Pulmonary Fibrosis: Recent Trials and Current Drug Therapy

Jones

Fletcher²,

Richeldi³

2013

Respiration

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease with increasing incidence; the median survival is only 35 months and as yet no therapy has been proven to prolong survival. Recent unexpected randomised controlled trial (RCT) results and the conflicting evaluations of drug efficacy by regulatory agencies when considering the approval of pirfenidone have emphasised that we remain in the first stages of both our understanding of disease-relevant therapeutic targets and in our ability to investigate these putative targets with well-designed RCT. Three phase III trials are, however, anticipated to report results in 2014 and there is cautious optimism that we may be entering an era of mechanism-based anti-fibrotic therapies proven by large RCT to modify disease progression. We must now address how to practically translate these therapies safely and with maximal efficacy from a homogenous RCT population to the ‘real-life' heterogeneous population of patients with IPF. The role of a formal multi-disciplinary team meeting in a specialist centre with expertise in IPF is key to this. New methodological and ethical research challenges will arise as we enter an era of potential combination therapy; standardized, robust RCT design will be central to meeting these challenges if we are to enable ongoing progress in our aim of increasing both the length and quality of life of patients with IPF.

show abstract

Toxicidad pulmonar por talidomida

Cited by 27 publications

References 25 publications

Thalidomide Induced Nonspecific Interstitial Pneumonia in Patient with Relapsed Multiple Myeloma

Thalidomide Induced Nonspecific Interstitial Pneumonia in Patient with Relapsed Multiple Myeloma

Amyloidosis and the Lungs and Airways

Idiopathic Pulmonary Fibrosis: Recent Trials and Current Drug Therapy

Contact Info

Product

Resources

About